The Daily Buyout
$100MDivestiture / carve-outHealthcare & Life SciencesCompleted

Harrow closes TYRVAYA buy from Viatris for up to $100M

Harrow has completed its acquisition of TYRVAYA nasal spray, the first and only FDA-approved nasal spray for dry eye disease, from Viatris. Harrow paid $30 million in cash at closing from cash on hand and may pay up to $70 million in milestones tied to net sales, for potential total consideration of $100 million. Harrow acquired worldwide rights except Japan, where Viatris retains commercialization and will pay royalties.

Why it matters: The deal gives Harrow a second differentiated branded dry-eye product alongside VEVYE in a large and growing U.S. market.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

Following healthcare M&A?

The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.

Free · Unsubscribe anytime

See what you get →